Seeking Alpha

Affymax (AFFY -63.4%) shares plunge on data that shows safety risks for its anemia drug...

Affymax (AFFY -63.4%) shares plunge on data that shows safety risks for its anemia drug Hematide. Non-dialysis patients taking the drug had a higher rate of cardiovascular events, including heart attacks, strokes and death, than those taking Amgen's (AMGN +4.1%) Epogen.
From other sites
Comments (1)
  • Duude
    , contributor
    Comments (3401) | Send Message
     
    Cyclists didn't like its half-life in the bloodstream either.
    21 Jun 2010, 10:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs